Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
ST5 was identified by its ability to suppress the tumorigenicity of Hela cells in nude mice. Additionally we are shipping Suppression of Tumorigenicity 5 Proteins (3) and Suppression of Tumorigenicity 5 Kits (2) and many more products for this protein.
Showing 10 out of 58 products:
Here, we discover that intersectin-s binds DENND2B, a guanine nucleotide exchange factor (show RASGRF1 Antibodies) for the exocytic GTPase (show RACGAP1 Antibodies) Rab13 (show RAB13 Antibodies), and this interaction promotes recycling of ligand-free EGFR (show EGFR Antibodies) to the cell surface. Our study thus reveals a novel mechanism controlling the fate of internalized EGFR (show EGFR Antibodies) with important implications for cancer.
DENND2B interacts with the Rab13 (show RAB13 Antibodies) effector MICAL-L2 (show MICALL2 Antibodies) at the cell periphery, and this interaction is required for the dynamic remodeling of the cell's leading edge.
Using RNA in situ hybridisation in mouse, the authors found that St5 is expressed in the frontal cortex during embryonic development. In adult mouse brain, expression of St5 was especially high in the hippocampal area and cerebellum.
This gene was identified by its ability to suppress the tumorigenicity of Hela cells in nude mice. The protein encoded by this gene contains a C-terminal region that shares similarity with the Rab 3 family of small GTP binding proteins. This protein preferentially binds to the SH3 domain of c-Abl kinase, and acts as a regulator of MAPK1/ERK2 kinase, which may contribute to its ability to reduce the tumorigenic phenotype in cells. Three alternatively spliced transcript variants of this gene encoding distinct isoforms are identified.
suppression of tumorigenicity 5
, suppression of tumorigenicity 5 protein
, DENN/MADD domain containing 2B
, heLa tumor suppression 1
, DENN domain-containing protein 2B